Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD2-305 extension study
jRCT2080225237Phase 3Completed
- Sponsor
- KM Biologics
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Byclot in hemophilia with inhibitor and coagulopathy, sponsored by KM Biologics. Started Jun 2020; status: completed.
02
Drugs
Byclot
03
Conditions
hemophilia with inhibitorcoagulopathy
Beyond the preview
Go deeper on jRCT2080225237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225237.